http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Fri, 13 Mar 2026 16:11:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++3++++++++++Werewolf+Therapeutics%2C++++For%3A+Feb+13++Filed+by%3A+Urban+Michael+J./26159631.html si-local-file:///var/storage/secattach/20260313/26159631.html http://www.streetinsider.com/SEC+Filings/Form++3++++++++++Werewolf+Therapeutics%2C++++For%3A+Feb+13++Filed+by%3A+Urban+Michael+J./26159631.html Fri, 13 Mar 2026 16:11:00 -0400 HOWL O.50483745 http://www.streetinsider.com/SEC+Filings/Form++3++++++++++Werewolf+Therapeutics%2C++++For%3A+Feb+13++Filed+by%3A+Urban+Michael+J./26159631.html si-local-file:///var/storage/secattach/20260313/26159631.html http://www.streetinsider.com/SEC+Filings/Form++3++++++++++Werewolf+Therapeutics%2C++++For%3A+Feb+13++Filed+by%3A+Urban+Michael+J./26159631.html Fri, 13 Mar 2026 16:11:00 -0400 HOWL O.50483745 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Werewolf+Therapeutics%2C++++For%3A+Feb+24/26053152.html si-local-file:///var/storage/secattach/20260224/26053152.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Werewolf+Therapeutics%2C++++For%3A+Feb+24/26053152.html Tue, 24 Feb 2026 17:27:00 -0400 HOWL O.50483745 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Werewolf+Therapeutics%2C++++For%3A+Feb+24/26053152.html si-local-file:///var/storage/secattach/20260224/26053152.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Werewolf+Therapeutics%2C++++For%3A+Feb+24/26053152.html Tue, 24 Feb 2026 17:27:00 -0400 HOWL O.50483745 http://www.streetinsider.com/Mergers+and+Acquisitions/Werewolf+Therapeutics+explores+strategic+alternatives+including+sale/26051559.html <p>Werewolf Therapeutics Inc. (NASDAQ: HOWL) announced it will explore strategic alternatives to maximize stockholder value, according to a company statement. The biopharmaceutical company has engaged Piper Sandler & Co. as its exclusive financial advisor for the evaluation process.</p> <p>The strategic alternatives under consideration include a sale of the company, business combination or merger, asset sales, licensing or collaboration arrangements, or other strategic transactions, said Dan Hicklin, president and CEO of Werewolf Therapeutics.</p> <p>The company develops therapeutics designed to stimulate immune system responses for cancer and other immune-mediated conditions. Its clinical-stage product candidates include WTX-124 and WTX-330, which are conditionally activated molecules targeting http://www.streetinsider.com/Mergers+and+Acquisitions/Werewolf+Therapeutics+explores+strategic+alternatives+including+sale/26051559.html Tue, 24 Feb 2026 16:10:43 -0400 A.16510096 HOWL O.50483745 O.51342700 http://www.streetinsider.com/Mergers+and+Acquisitions/Werewolf+Therapeutics+explores+strategic+alternatives+including+sale/26051559.html <p>Werewolf Therapeutics Inc. (NASDAQ: HOWL) announced it will explore strategic alternatives to maximize stockholder value, according to a company statement. The biopharmaceutical company has engaged Piper Sandler & Co. as its exclusive financial advisor for the evaluation process.</p> <p>The strategic alternatives under consideration include a sale of the company, business combination or merger, asset sales, licensing or collaboration arrangements, or other strategic transactions, said Dan Hicklin, president and CEO of Werewolf Therapeutics.</p> <p>The company develops therapeutics designed to stimulate immune system responses for cancer and other immune-mediated conditions. Its clinical-stage product candidates include WTX-124 and WTX-330, which are conditionally activated molecules targeting http://www.streetinsider.com/Mergers+and+Acquisitions/Werewolf+Therapeutics+explores+strategic+alternatives+including+sale/26051559.html Tue, 24 Feb 2026 16:10:43 -0400 A.16510096 HOWL O.50483745 O.51342700 http://www.streetinsider.com/Mergers+and+Acquisitions/Werewolf+Therapeutics+explores+strategic+alternatives+including+sale/26051559.html <p>Werewolf Therapeutics Inc. (NASDAQ: HOWL) announced it will explore strategic alternatives to maximize stockholder value, according to a company statement. The biopharmaceutical company has engaged Piper Sandler & Co. as its exclusive financial advisor for the evaluation process.</p> <p>The strategic alternatives under consideration include a sale of the company, business combination or merger, asset sales, licensing or collaboration arrangements, or other strategic transactions, said Dan Hicklin, president and CEO of Werewolf Therapeutics.</p> <p>The company develops therapeutics designed to stimulate immune system responses for cancer and other immune-mediated conditions. Its clinical-stage product candidates include WTX-124 and WTX-330, which are conditionally activated molecules targeting http://www.streetinsider.com/Mergers+and+Acquisitions/Werewolf+Therapeutics+explores+strategic+alternatives+including+sale/26051559.html Tue, 24 Feb 2026 16:10:43 -0400 A.16510096 HOWL O.50483745 O.51342700 http://www.streetinsider.com/Mergers+and+Acquisitions/Werewolf+Therapeutics+explores+strategic+alternatives+including+sale/26051559.html <p>Werewolf Therapeutics Inc. (NASDAQ: HOWL) announced it will explore strategic alternatives to maximize stockholder value, according to a company statement. The biopharmaceutical company has engaged Piper Sandler & Co. as its exclusive financial advisor for the evaluation process.</p> <p>The strategic alternatives under consideration include a sale of the company, business combination or merger, asset sales, licensing or collaboration arrangements, or other strategic transactions, said Dan Hicklin, president and CEO of Werewolf Therapeutics.</p> <p>The company develops therapeutics designed to stimulate immune system responses for cancer and other immune-mediated conditions. Its clinical-stage product candidates include WTX-124 and WTX-330, which are conditionally activated molecules targeting http://www.streetinsider.com/Mergers+and+Acquisitions/Werewolf+Therapeutics+explores+strategic+alternatives+including+sale/26051559.html Tue, 24 Feb 2026 16:10:43 -0400 A.16510096 HOWL O.50483745 O.51342700 http://www.streetinsider.com/Press+Releases/Werewolf+Therapeutics+Announces+Plan+to+Explore+Strategic+Alternatives/26051523.html <p align="justify">WATERTOWN, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (Nasdaq: HOWL) (the “Company” or “Werewolf”), an innovative biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body’s immune system for the treatment of cancer and other immune-mediated conditions, today announced that the Company will explore a full range of strategic alternatives to advance its promising platform and drug development pipeline to maximize stockholder value. The Company has engaged Piper Sandler &amp; Co. (“Piper Sandler”) to serve as exclusive financial advisor to assist in the strategic evaluation process.</p> <p align="justify">“We have initiated a http://www.streetinsider.com/Press+Releases/Werewolf+Therapeutics+Announces+Plan+to+Explore+Strategic+Alternatives/26051523.html Tue, 24 Feb 2026 16:09:00 -0400 A.16510096 HOWL O.50483745 O.51342700 http://www.streetinsider.com/Press+Releases/Werewolf+Therapeutics+Announces+Plan+to+Explore+Strategic+Alternatives/26051523.html <p align="justify">WATERTOWN, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (Nasdaq: HOWL) (the “Company” or “Werewolf”), an innovative biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body’s immune system for the treatment of cancer and other immune-mediated conditions, today announced that the Company will explore a full range of strategic alternatives to advance its promising platform and drug development pipeline to maximize stockholder value. The Company has engaged Piper Sandler &amp; Co. (“Piper Sandler”) to serve as exclusive financial advisor to assist in the strategic evaluation process.</p> <p align="justify">“We have initiated a http://www.streetinsider.com/Press+Releases/Werewolf+Therapeutics+Announces+Plan+to+Explore+Strategic+Alternatives/26051523.html Tue, 24 Feb 2026 16:09:00 -0400 A.16510096 HOWL O.50483745 O.51342700 http://www.streetinsider.com/Press+Releases/Werewolf+Therapeutics+Announces+Plan+to+Explore+Strategic+Alternatives/26051523.html <p align="justify">WATERTOWN, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (Nasdaq: HOWL) (the “Company” or “Werewolf”), an innovative biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body’s immune system for the treatment of cancer and other immune-mediated conditions, today announced that the Company will explore a full range of strategic alternatives to advance its promising platform and drug development pipeline to maximize stockholder value. The Company has engaged Piper Sandler &amp; Co. (“Piper Sandler”) to serve as exclusive financial advisor to assist in the strategic evaluation process.</p> <p align="justify">“We have initiated a http://www.streetinsider.com/Press+Releases/Werewolf+Therapeutics+Announces+Plan+to+Explore+Strategic+Alternatives/26051523.html Tue, 24 Feb 2026 16:09:00 -0400 A.16510096 HOWL O.50483745 O.51342700 http://www.streetinsider.com/Press+Releases/Werewolf+Therapeutics+Announces+Plan+to+Explore+Strategic+Alternatives/26051523.html <p align="justify">WATERTOWN, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (Nasdaq: HOWL) (the “Company” or “Werewolf”), an innovative biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body’s immune system for the treatment of cancer and other immune-mediated conditions, today announced that the Company will explore a full range of strategic alternatives to advance its promising platform and drug development pipeline to maximize stockholder value. The Company has engaged Piper Sandler &amp; Co. (“Piper Sandler”) to serve as exclusive financial advisor to assist in the strategic evaluation process.</p> <p align="justify">“We have initiated a http://www.streetinsider.com/Press+Releases/Werewolf+Therapeutics+Announces+Plan+to+Explore+Strategic+Alternatives/26051523.html Tue, 24 Feb 2026 16:09:00 -0400 A.16510096 HOWL O.50483745 O.51342700 http://www.streetinsider.com/Globe+Newswire/Werewolf+Therapeutics+Announces+Plan+to+Explore+Strategic+Alternatives/26051523.html <p align="justify">WATERTOWN, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (Nasdaq: HOWL) (the “Company” or “Werewolf”), an innovative biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body’s immune system for the treatment of cancer and other immune-mediated conditions, today announced that the Company will explore a full range of strategic alternatives to advance its promising platform and drug development pipeline to maximize stockholder value. The Company has engaged Piper Sandler &amp; Co. (“Piper Sandler”) to serve as exclusive financial advisor to assist in the strategic evaluation process.</p> <p align="justify">“We have initiated a http://www.streetinsider.com/Globe+Newswire/Werewolf+Therapeutics+Announces+Plan+to+Explore+Strategic+Alternatives/26051523.html Tue, 24 Feb 2026 16:09:00 -0400 A.16510096 HOWL O.50483745 O.51342700 http://www.streetinsider.com/Globe+Newswire/Werewolf+Therapeutics+Announces+Plan+to+Explore+Strategic+Alternatives/26051523.html <p align="justify">WATERTOWN, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (Nasdaq: HOWL) (the “Company” or “Werewolf”), an innovative biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body’s immune system for the treatment of cancer and other immune-mediated conditions, today announced that the Company will explore a full range of strategic alternatives to advance its promising platform and drug development pipeline to maximize stockholder value. The Company has engaged Piper Sandler &amp; Co. (“Piper Sandler”) to serve as exclusive financial advisor to assist in the strategic evaluation process.</p> <p align="justify">“We have initiated a http://www.streetinsider.com/Globe+Newswire/Werewolf+Therapeutics+Announces+Plan+to+Explore+Strategic+Alternatives/26051523.html Tue, 24 Feb 2026 16:09:00 -0400 A.16510096 HOWL O.50483745 O.51342700 http://www.streetinsider.com/Globe+Newswire/Werewolf+Therapeutics+Announces+Plan+to+Explore+Strategic+Alternatives/26051523.html <p align="justify">WATERTOWN, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (Nasdaq: HOWL) (the “Company” or “Werewolf”), an innovative biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body’s immune system for the treatment of cancer and other immune-mediated conditions, today announced that the Company will explore a full range of strategic alternatives to advance its promising platform and drug development pipeline to maximize stockholder value. The Company has engaged Piper Sandler &amp; Co. (“Piper Sandler”) to serve as exclusive financial advisor to assist in the strategic evaluation process.</p> <p align="justify">“We have initiated a http://www.streetinsider.com/Globe+Newswire/Werewolf+Therapeutics+Announces+Plan+to+Explore+Strategic+Alternatives/26051523.html Tue, 24 Feb 2026 16:09:00 -0400 A.16510096 HOWL O.50483745 O.51342700 http://www.streetinsider.com/Globe+Newswire/Werewolf+Therapeutics+Announces+Plan+to+Explore+Strategic+Alternatives/26051523.html <p align="justify">WATERTOWN, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (Nasdaq: HOWL) (the “Company” or “Werewolf”), an innovative biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body’s immune system for the treatment of cancer and other immune-mediated conditions, today announced that the Company will explore a full range of strategic alternatives to advance its promising platform and drug development pipeline to maximize stockholder value. The Company has engaged Piper Sandler &amp; Co. (“Piper Sandler”) to serve as exclusive financial advisor to assist in the strategic evaluation process.</p> <p align="justify">“We have initiated a http://www.streetinsider.com/Globe+Newswire/Werewolf+Therapeutics+Announces+Plan+to+Explore+Strategic+Alternatives/26051523.html Tue, 24 Feb 2026 16:09:00 -0400 A.16510096 HOWL O.50483745 O.51342700 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Werewolf+Therapeutics%2C++++For%3A+Feb+09/26000603.html si-local-file:///var/storage/secattach/20260213/26000603.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Werewolf+Therapeutics%2C++++For%3A+Feb+09/26000603.html Fri, 13 Feb 2026 16:21:00 -0400 HOWL O.50483745 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Werewolf+Therapeutics%2C++++For%3A+Feb+09/26000603.html si-local-file:///var/storage/secattach/20260213/26000603.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Werewolf+Therapeutics%2C++++For%3A+Feb+09/26000603.html Fri, 13 Feb 2026 16:21:00 -0400 HOWL O.50483745 http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Werewolf+Therapeutics%2C+++++++++++++++++Filed+by%3A+Longwood+Fund+III%2C+L.P./25982945.html si-local-file:///var/storage/secattach/20260211/25982945.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Werewolf+Therapeutics%2C+++++++++++++++++Filed+by%3A+Longwood+Fund+III%2C+L.P./25982945.html Wed, 11 Feb 2026 15:46:00 -0400 HOWL O.50483745 http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Werewolf+Therapeutics%2C+++++++++++++++++Filed+by%3A+Longwood+Fund+III%2C+L.P./25982945.html si-local-file:///var/storage/secattach/20260211/25982945.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Werewolf+Therapeutics%2C+++++++++++++++++Filed+by%3A+Longwood+Fund+III%2C+L.P./25982945.html Wed, 11 Feb 2026 15:46:00 -0400 HOWL O.50483745 http://www.streetinsider.com/Corporate+News/Werewolf+Therapeutics+receives+Nasdaq+deficiency+notice+for+low+stock+price/25962283.html <p>Werewolf Therapeutics Inc. (NASDAQ: HOWL) received a deficiency letter from Nasdaq on February 4, 2026, notifying the company that its stock price had closed below $1.00 per share for 30 consecutive business days, according to a press release.</p><p>The biotechnology company's stock failed to meet Nasdaq's minimum bid price requirement of $1.00 per share for continued listing on the Nasdaq Global Select Market under Rule 5450(a)(1).</p><p>The notice does not immediately affect the listing of Werewolf's common stock. The company has 180 calendar days until August 3, 2026, to regain compliance with the minimum bid requirement. To meet compliance, the stock's closing http://www.streetinsider.com/Corporate+News/Werewolf+Therapeutics+receives+Nasdaq+deficiency+notice+for+low+stock+price/25962283.html Fri, 06 Feb 2026 16:43:15 -0400 HOWL http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Werewolf+Therapeutics%2C++++For%3A+Feb+04/25962263.html si-local-file:///var/storage/secattach/20260206/25962263.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Werewolf+Therapeutics%2C++++For%3A+Feb+04/25962263.html Fri, 06 Feb 2026 16:41:00 -0400 HOWL O.50483745 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Werewolf+Therapeutics%2C++++For%3A+Feb+04/25962263.html si-local-file:///var/storage/secattach/20260206/25962263.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Werewolf+Therapeutics%2C++++For%3A+Feb+04/25962263.html Fri, 06 Feb 2026 16:41:00 -0400 HOWL O.50483745 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Werewolf+Therapeutics%2C++++For%3A+Jan+16++Filed+by%3A+EVNIN+LUKE/25868213.html si-local-file:///var/storage/secattach/20260120/25868213.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Werewolf+Therapeutics%2C++++For%3A+Jan+16++Filed+by%3A+EVNIN+LUKE/25868213.html Tue, 20 Jan 2026 16:08:00 -0400 HOWL O.50483745 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Werewolf+Therapeutics%2C++++For%3A+Jan+16++Filed+by%3A+EVNIN+LUKE/25868213.html si-local-file:///var/storage/secattach/20260120/25868213.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Werewolf+Therapeutics%2C++++For%3A+Jan+16++Filed+by%3A+EVNIN+LUKE/25868213.html Tue, 20 Jan 2026 16:08:00 -0400 HOWL O.50483745